Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson’s Disease

Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkin...

Full description

Saved in:
Bibliographic Details
Published inEuropean neurology Vol. 65; no. 2; pp. 105 - 111
Main Authors Li, Yao-Hua, Wang, Jian, Zheng, Xiao-Li, Zhang, Yan-Li, Li, Xin, Yu, Shun, He, Xin, Chan, Piu
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.02.2011
Subjects
Online AccessGet full text
ISSN0014-3022
1421-9913
1421-9913
DOI10.1159/000323427

Cover

Abstract Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson’s disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.
AbstractList Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson’s disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.
Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology.BACKGROUNDBiomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology.Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model.METHODSSerum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model.A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%.RESULTSA total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%.The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.CONCLUSIONSThe preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.
Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Copyright [copy 2011 S. Karger AG, Basel
Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Copyright © 2011 S. Karger AG, Basel [PUBLICATION ABSTRACT]
Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.
Author Wang, Jian
Li, Yao-Hua
Chan, Piu
Zheng, Xiao-Li
Zhang, Yan-Li
He, Xin
Li, Xin
Yu, Shun
Author_xml – sequence: 1
  givenname: Yao-Hua
  surname: Li
  fullname: Li, Yao-Hua
  email: liyaohua1962@yahoo.com.cn
– sequence: 2
  givenname: Jian
  surname: Wang
  fullname: Wang, Jian
– sequence: 3
  givenname: Xiao-Li
  surname: Zheng
  fullname: Zheng, Xiao-Li
– sequence: 4
  givenname: Yan-Li
  surname: Zhang
  fullname: Zhang, Yan-Li
– sequence: 5
  givenname: Xin
  surname: Li
  fullname: Li, Xin
  email: liyaohua1962@yahoo.com.cn
– sequence: 6
  givenname: Shun
  surname: Yu
  fullname: Yu, Shun
– sequence: 7
  givenname: Xin
  surname: He
  fullname: He, Xin
– sequence: 8
  givenname: Piu
  surname: Chan
  fullname: Chan, Piu
  email: liyaohua1962@yahoo.com.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21273779$$D View this record in MEDLINE/PubMed
BookMark eNqFks9u1DAQxi1URLeFA3eELC4Vh7D-E8fJsd1SqLQVlVrOkZNMtm439uJxBO2J1-AReC2eBC-77KFC4jQzmt98suebA7LnvANCXnL2jnNVTRljUshc6CdkwnPBs6rico9MGON5JpkQ--QA8TaVqtLlM7IvuNBS62pCfl6YGOy37BjRYoSOzg1CoKeAPqyi9W567p19MOuUXtsBMt9nZ0u7uIn0wiDSqxW0MfgBYrinMz801iWVrzbepP7CQbQtPQHTIe39Wjcm3LoFvYIwDvQy-AjW0RPrBxPuICBN1WVKrUPvfn3_gfTUIqRHPSdPe7NEeLGNh-Tz2fvr2cds_unD-ex4nrWyyGOmgBXKVKoxTSmUMn3B8hxaqUthyrwqDWdKs64Qus_bTpZFztqOdVxB33UNGHlIjja6q-C_jICxHiy2sFwaB37Euiy0llKK4v-kksmISupEvnlE3voxuPSNBOVCca5Vgl5vobEZoKtXwaad3Nd_zUrA2w3QBo8YoN8hnNXrQ6h3h5DY6SO2tfGPizEYu_znxKvNxJ0JCwg77W37NyMUv4c
CODEN EUNEAP
CitedBy_id crossref_primary_10_1016_j_bbapap_2015_01_016
crossref_primary_10_1007_s12035_013_8590_8
crossref_primary_10_1371_journal_pone_0079733
crossref_primary_10_1002_jcla_21694
crossref_primary_10_1007_s12010_013_0238_7
crossref_primary_10_1016_j_pneurobio_2011_09_002
crossref_primary_10_1007_s13758_012_0066_2
crossref_primary_10_3109_15622975_2011_598712
crossref_primary_10_1007_s12640_019_00080_4
crossref_primary_10_1002_mds_26635
crossref_primary_10_1586_14737175_2016_1135056
crossref_primary_10_1002_mds_25065
crossref_primary_10_1042_BSR20150023
crossref_primary_10_1016_j_neuint_2013_06_005
Cites_doi 10.1093%2Fbrain%2F114.5.2283
10.1038%2F35086067
10.1097%2FMLG.0b013e31814cf389
10.1016%2FS0304-3940%2802%2901259-4
10.1074%2Fmcp.R200007-MCP200
10.1200%2FJCO.2005.03.164
10.1093%2Fhmg%2Fddm159
10.1038%2Fnm1113
10.1016%2Fj.schres.2006.02.016
10.1002%2Fmds.10305
10.1021%2Fpr0703526
10.1136%2Fjnnp.55.3.181
10.1373%2Fclinchem.2004.032458
10.1038%2Fnrc2011
10.1002%2Fana.410240415
10.1146%2Fannurev.neuro.28.061604.135718
ContentType Journal Article
Copyright 2011 S. Karger AG, Basel
Copyright © 2011 S. Karger AG, Basel.
Copyright (c) 2011 S. Karger AG, Basel
Copyright_xml – notice: 2011 S. Karger AG, Basel
– notice: Copyright © 2011 S. Karger AG, Basel.
– notice: Copyright (c) 2011 S. Karger AG, Basel
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
88G
88I
8AF
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
M2M
M2P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
S0X
7X8
DOI 10.1159/000323427
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
Psychology Database (ProQuest)
Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
SIRS Editorial
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
Neurosciences Abstracts
ProQuest One Psychology

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central Database Suite (ProQuest)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1421-9913
EndPage 111
ExternalDocumentID 2279246501
21273779
10_1159_000323427
323427
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0~5
0~B
29G
30W
325
34G
36B
39C
3O.
3V.
4.4
53G
5GY
5RE
7X7
88E
88I
8AF
8AO
8FI
8FJ
8UI
AAYIC
ABIVO
ABJNI
ABPAZ
ABUWG
ACGFO
ACGFS
ACGOD
ACPRK
ACPSR
ADAGL
ADBBV
ADFRT
ADGES
AENEX
AEYAO
AFJJK
AFKRA
AFOSN
AHMBA
AI.
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZPMC
AZQEC
BENPR
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CYUIP
DU5
DWQXO
E0A
EBS
EJD
EMB
EMOBN
F5P
FB.
FYUFA
GNUQQ
HCIFZ
HMCUK
HZ~
IY7
KUZGX
M1P
M2M
M2P
N9A
O1H
O9-
P2P
PQQKQ
PROAC
PSQYO
PSYQQ
RIG
RKO
RXVBD
S0X
SV3
UJ6
UKHRP
VH1
X7M
ZGI
ZXP
AAYXX
ABBTS
ABWCG
ACQXL
AFSIO
AHFRZ
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7TK
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c364t-5e065a95bab8255af6044ec3782a8498a10570d627f4cd38640cd0d15efddbea3
IEDL.DBID 7X7
ISSN 0014-3022
1421-9913
IngestDate Thu Sep 04 16:15:25 EDT 2025
Fri Sep 05 03:16:29 EDT 2025
Sat Aug 23 13:31:27 EDT 2025
Mon Jul 21 05:29:42 EDT 2025
Thu Apr 24 23:12:00 EDT 2025
Tue Jul 01 05:10:22 EDT 2025
Thu Aug 29 12:04:14 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Parkinsonߣs disease
MALDI-TOF-MS
Weak cationic exchange magnetic beads
Proteomics
Biomarkers diagnosis
Language English
License Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
https://www.karger.com/Services/SiteLicenses
Copyright © 2011 S. Karger AG, Basel.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c364t-5e065a95bab8255af6044ec3782a8498a10570d627f4cd38640cd0d15efddbea3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 21273779
PQID 854251175
PQPubID 41501
PageCount 7
ParticipantIDs proquest_miscellaneous_867733326
crossref_primary_10_1159_000323427
proquest_miscellaneous_853991937
karger_primary_323427
pubmed_primary_21273779
proquest_journals_854251175
crossref_citationtrail_10_1159_000323427
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-02-00
PublicationDateYYYYMMDD 2011-02-01
PublicationDate_xml – month: 02
  year: 2011
  text: 2011-02-00
PublicationDecade 2010
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
– name: Basel
PublicationTitle European neurology
PublicationTitleAlternate Eur Neurol
PublicationYear 2011
Publisher S. Karger AG
Publisher_xml – name: S. Karger AG
References Thomas B, Beal MF: Parkinson’s disease. Hum Mol Genet 2007;16:183–194.10.1093%2Fhmg%2Fddm159
Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005;23:5088–5093.1605195510.1200%2FJCO.2005.03.164
Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci Lett 2003;336:105–108.1249905110.1016%2FS0304-3940%2802%2901259-4
Lin XL, Yang SY, Du J, Tian YX, Bu LN, Huo SF, Wang FP, Nan YD: Detection of lung adenocarcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J 2010;123:34–39.20137572
Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR: Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 2008;118:61–68.1804349710.1097%2FMLG.0b013e31814cf389
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.156447610.1136%2Fjnnp.55.3.181
McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P: Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2001;2:589–594.1148400210.1038%2F35086067
Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and Regression Trees. Belmont, Wadsworth, 1984.
Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19–31.1251829710.1002%2Fmds.10305
Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.12142387
Pahwa R, Lyons KE: Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16:94–99.
Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961–967.1709350410.1038%2Fnrc2011
Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.1248846110.1074%2Fmcp.R200007-MCP200
Dotzlaw H, Schulz M, Eggert M, Neeck G: A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004;1696:121–129.14726212
Forman MS, Trojanowski JQ, Lee VM: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–1063.1545970910.1038%2Fnm1113
Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, Wang Y, Chen M, Wu D, Wang Y, Bi S, Qiu Y, Lu P, Cheng J, Xiao B, Hu L, Gao X, Liu J, Wang Y, Song Y, Zhang L, Suo F, Chen T, Huang Z, Zhao Y, Lu H, Pan C, Tang H: Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56–64.1555047910.1373%2Fclinchem.2004.032458
McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574–576.323995710.1002%2Fana.410240415
Gatlin-Bunai CL, Cazares LH, Cooke WE, Semmes OJ, Malyarenko DI: Optimization of MALDI-TOF-MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100-kDa mass range. J Proteome Res 2007;6:4517–4524.1791887410.1021%2Fpr0703526
Zhang X, Leung SM, Morris CR, Shigenaga MK: Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004;15:167–175.15331582
Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005;28:57–87.1602259010.1146%2Fannurev.neuro.28.061604.135718
Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.193324510.1093%2Fbrain%2F114.5.2283
Mei J, Kolbin D, Kao HT, Porton B: Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006;84:204–213.1662453210.1016%2Fj.schres.2006.02.016
McDonald WH, Yates JR: Shotgun proteomics and biomarker discovery. Dis Markers 2002;18:99–105.12364816
ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref16
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – reference: Pahwa R, Lyons KE: Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16:94–99.
– reference: Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005;23:5088–5093.1605195510.1200%2FJCO.2005.03.164
– reference: Forman MS, Trojanowski JQ, Lee VM: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–1063.1545970910.1038%2Fnm1113
– reference: Gatlin-Bunai CL, Cazares LH, Cooke WE, Semmes OJ, Malyarenko DI: Optimization of MALDI-TOF-MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100-kDa mass range. J Proteome Res 2007;6:4517–4524.1791887410.1021%2Fpr0703526
– reference: Dotzlaw H, Schulz M, Eggert M, Neeck G: A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004;1696:121–129.14726212
– reference: Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005;28:57–87.1602259010.1146%2Fannurev.neuro.28.061604.135718
– reference: Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR: Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 2008;118:61–68.1804349710.1097%2FMLG.0b013e31814cf389
– reference: Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.12142387
– reference: Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.193324510.1093%2Fbrain%2F114.5.2283
– reference: Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci Lett 2003;336:105–108.1249905110.1016%2FS0304-3940%2802%2901259-4
– reference: Zhang X, Leung SM, Morris CR, Shigenaga MK: Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004;15:167–175.15331582
– reference: Lin XL, Yang SY, Du J, Tian YX, Bu LN, Huo SF, Wang FP, Nan YD: Detection of lung adenocarcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J 2010;123:34–39.20137572
– reference: McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574–576.323995710.1002%2Fana.410240415
– reference: Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.1248846110.1074%2Fmcp.R200007-MCP200
– reference: McDonald WH, Yates JR: Shotgun proteomics and biomarker discovery. Dis Markers 2002;18:99–105.12364816
– reference: Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19–31.1251829710.1002%2Fmds.10305
– reference: Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and Regression Trees. Belmont, Wadsworth, 1984.
– reference: Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961–967.1709350410.1038%2Fnrc2011
– reference: Thomas B, Beal MF: Parkinson’s disease. Hum Mol Genet 2007;16:183–194.10.1093%2Fhmg%2Fddm159
– reference: Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.156447610.1136%2Fjnnp.55.3.181
– reference: Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, Wang Y, Chen M, Wu D, Wang Y, Bi S, Qiu Y, Lu P, Cheng J, Xiao B, Hu L, Gao X, Liu J, Wang Y, Song Y, Zhang L, Suo F, Chen T, Huang Z, Zhao Y, Lu H, Pan C, Tang H: Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56–64.1555047910.1373%2Fclinchem.2004.032458
– reference: McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P: Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2001;2:589–594.1148400210.1038%2F35086067
– reference: Mei J, Kolbin D, Kao HT, Porton B: Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006;84:204–213.1662453210.1016%2Fj.schres.2006.02.016
– ident: ref2
  doi: 10.1093%2Fbrain%2F114.5.2283
– ident: ref5
  doi: 10.1038%2F35086067
– ident: ref16
  doi: 10.1097%2FMLG.0b013e31814cf389
– ident: ref13
  doi: 10.1016%2FS0304-3940%2802%2901259-4
– ident: ref6
  doi: 10.1074%2Fmcp.R200007-MCP200
– ident: ref8
  doi: 10.1200%2FJCO.2005.03.164
– ident: ref1
  doi: 10.1093%2Fhmg%2Fddm159
– ident: ref10
  doi: 10.1038%2Fnm1113
– ident: ref9
  doi: 10.1016%2Fj.schres.2006.02.016
– ident: ref12
  doi: 10.1002%2Fmds.10305
– ident: ref14
  doi: 10.1021%2Fpr0703526
– ident: ref3
  doi: 10.1136%2Fjnnp.55.3.181
– ident: ref7
  doi: 10.1373%2Fclinchem.2004.032458
– ident: ref15
  doi: 10.1038%2Fnrc2011
– ident: ref4
  doi: 10.1002%2Fana.410240415
– ident: ref11
  doi: 10.1146%2Fannurev.neuro.28.061604.135718
SSID ssj0015978
Score 2.0187845
Snippet Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search...
Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel...
SourceID proquest
pubmed
crossref
karger
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 105
SubjectTerms Adult
Aged
Biomarkers - blood
Blood Proteins - analysis
Female
Humans
Immunomagnetic Separation - methods
Male
Middle Aged
Original Paper
Parkinson Disease - blood
Parkinson Disease - diagnosis
Proteomics - methods
Sensitivity and Specificity
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
Young Adult
Title Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson’s Disease
URI https://karger.com/doi/10.1159/000323427
https://www.ncbi.nlm.nih.gov/pubmed/21273779
https://www.proquest.com/docview/854251175
https://www.proquest.com/docview/853991937
https://www.proquest.com/docview/867733326
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RQEB60FfFFvFRdq-Uggr4cmm7ObZ_E1S5V3FLEwr6Fc9tSbJM2yUL9Rf5NZ5KT4IP2cZMhgZ3JzDdnZr4BeOu0iUF5Wu4SDRchGO6cM9wHb5VR0maehpOXx-roVHxdyVXqzWlSW-XgEztHHSpPZ-T7RgpCw1p-uLrmtDSKiqtpg8Zd2O6Yy9Cc9WrMtzBQD46YDv-n00QshNdpfiGf5oJ2yfwVju79pO7r-v9gsws6i0fwMKFF9rFX72O4E8sncH-Z6uFP4feSGPZvOP7JpK7AvmFQqhkmk1Xd-YL9L9Uwaclo2oNXa764oIScLRE2M1o_3xJjQVv_YugbME_Gp9DhLN4_K2nCkc3RDBqG4BafSyUHDHYMXczmkp0QycN5yebn1SW1-dQNw180SN3NlL1r2Oe-_rMDp4vDH5-OeFq9wH2uRMtlRGhiZ9JZhymktGuVCRF9jnjCGjEzltYDZ0FN9Vr4kBslMh-ycCDjOgQXbf4MtsqqjC-AGdpubf2BIiYaZdEfEI2dV85q45S2E3g_aKDwiZec1mNcFF1-ImfFqKwJvBlFr3oyjn8J7fRqHEWG67uDVov0nTbFaFUTYONd_MCoamLLWG1IBDEcwlx9i4jSOs8RCE_geW8u47uJQJ84HV_e-vZdeNCfVVObzCvYautNfI1gp3V7nUnvwfb88Pjk-x86-wA_
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VLQIuiEehS3lYCAQXq2niON4DQiztapduVhVqpd5Sx_aiqm1Skqygv4gT_5GZvMQBeusxycg5zHjmG4_nG4A3aaSclYaGuzjFhbWKp2mquLFGSyVD7RlqTo4XcnokvhyHx2vwu-uFoWuVnU-sHbXNDZ2Rb6tQEBqOwo-X3zkNjaLiajdBo7GKfXf1AzO28sNsF9X71vcne4efp7wdKsBNIEXFQ4dBV4_CVKeYHIV6KT0hnAkwUmolRkrT4FvPSj9aCmMDJYVnrGd3Qre0NnU6wHVvwbqghtYBrI_3Fgdf-7IFovPW9VO5wfdbKiN8Tx0TgR8Iml7zVwC8fUb3vYv_w9s6zE0ewP0Wn7JPjUE9hDWXPYI7cVuBfwy_YuL0_8lRrWQgls0xDBYM09e8qL3P9izvejsZ9ZfwfMkn53QEwGIE6owG3lfEkVAVVwy9EWbmuAodB-P3bxn1VLIxGl7JEE7julTkwPDK0KmtLtgB0UqcZmx8ml_QxaKiZPhErdt1F9u7ku02FacNOLoRvTyBQZZnbhOYonna2uxI4r6RGj0QEecZmepIpTLSQ3jfaSAxLRM6DeQ4T-qMKBwlvbKG8LoXvWzoP_4ltNGosRfp3m91Wk1az1AmvR0PgfVfcUtTnUZnLl-RCKJGBNbRNSIyioIAofcQnjbm0v-bKPuJRfLZtX9_BXenh_E8mc8W-1twrzkpp0s6z2FQFSv3AqFWlb5sDZzByU3vqT_Y3j0Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKQVUviEeBpTwsBIKLtWns2N4DQpRl1aXdqhJU2lvwK6hqN1mSXUF_Eb-Bf8dMXuIAvfUYZ2QfZjzzjedFyEurdPDS4XCXoJnwXjNrrWbOOyO1TEzksDh5diwPTsWneTLfIL-7WhhMq-x0Yq2ofeHwjXyoE4FoWCXDrM2KOBlP3i2_MxwghYHWbppGIyGH4fIHeG_V2-kYWP0qjicfv3w4YO2AAea4FCuWBDDAZpRYY8FRSkwmIyGC42A1jRYjbXAIbuRlrDLhPNdSRM5Hfi8Jmfc2GA773iA3FQdQBVdJzXtfD0BCZwQw8BDHbVMjWMfaCR5zgXNs_jKFt84x87v8P9CtDd7kDrndIlX6vhGtu2Qj5PfI1qyNxd8nv2bY3f8nAwajqHh6BAaxpODIFmWth4bToqvypFhpwoqMTS7wMYDOALLTz8t6As8irMpLCnoJfHTYBR-G4f-3HKsr6T6IYEUBWMO-GO4AQ0tBva0X9AQbTJzldP-sWGCKUVlR-MIi7rqe7XVFx03saYecXgtXHpDNvMjDI0I1TtY2bk9iFxxpQBdhCz0nrVHaSmUG5E3HgdS1PdFxNMdFWvtGySjtmTUgL3rSZdMI5F9EOw0be5JufbfjatrqiCrtJXpAaP8XLjdGbEweijWSAH4EiK2uIJFKcQ4gfEAeNuLSn43N-7Gf5OMrT39OtuAmpUfT48Ndst08mWO2zhOyuSrX4SlgrpV9Vks3JV-v-zr9Af5DP9c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Matrix-assisted+laser+desorption%2Fionization+time-of-flight+mass+spectrometry+combined+with+magnetic+beads+for+detecting+serum+protein+biomarkers+in+parkinson%27s+disease&rft.jtitle=European+neurology&rft.au=Li%2C+Yao-Hua&rft.au=Wang%2C+Jian&rft.au=Zheng%2C+Xiao-Li&rft.au=Zhang%2C+Yan-Li&rft.date=2011-02-01&rft.issn=1421-9913&rft.eissn=1421-9913&rft.volume=65&rft.issue=2&rft.spage=105&rft_id=info:doi/10.1159%2F000323427&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-3022&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-3022&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-3022&client=summon